Free 2-Day Shipping on Orders Over $200
GLP-2 T is studied as a dual incretin-receptor agonist analog, with laboratory research centered on GLP-1R/GIPR structure and pathway-selective signaling.
Despite the VIVO shorthand, GLP-2 T is not the intestinal hormone GLP-2. It is presented as a dual incretin-receptor agonist analog. That distinction should be explicit on the page to avoid confusion with glucagon-like peptide-2 biology.
Structural studies have resolved dual incretin agonists of this class in complexes with GLP-1 and GIP receptors and have examined how amino-acid sequence and lipid modification shape binding. Cell-based assays further compare cAMP signaling, beta-arrestin recruitment, receptor internalization, and responses across receptor variants.
The literature supports receptor-structure, biased-signaling, and comparative pharmacology experiments. It does not mean a VIVO material was used in the cited work, and it does not establish safety, efficacy, dosing, administration, or an expected outcome in humans or animals.
Peer-reviewed sources for the research summarised above. Vivo summarises published, third-party science and does not conduct or sponsor this research.